EU/3/15/1565 - orphan designation for treatment of hepatocellular carcinoma

2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson)
OrphanHuman

Overview

On 9 October 2015, orphan designation (EU/3/15/1565) was granted by the European Commission to PBS Regulatory Consulting Group Limited, United Kingdom, for 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide for the treatment of hepatocellular carcinoma.

Hepatocellular carcinoma is a primary cancer of the liver (a cancer that starts in the liver, rather than one that has spread to the liver from elsewhere in the body). It is more common in men than in women, and occurs mostly in people who have liver scarring (cirrhosis) or after infection with the hepatitis B or C viruses. Symptoms of the disease include pain and swelling in the abdomen, weight loss, weakness, loss of appetite and nausea.

Hepatocellular carcinoma is a serious disease and is life-threatening because it is often diagnosed at an advanced stage.

At the time of designation, hepatocellular carcinoma affected approximately 1 in 10,000 people in the European Union (EU). This was equivalent to a total of around 51,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).


*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).

At the time of designation, some patients with early stage hepatocellular carcinoma were treated with surgery to remove part of the liver. Chemotherapy (medicines to treat cancer) was generally used after surgery or on its own if surgery was not possible or the disease had spread to other parts of the body (metastatic disease). Nexavar (sorafenib) was authorised in the EU for use in hepatocellular carcinoma.

The sponsor has provided sufficient information to show that 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide might be of significant benefit for patients with hepatocellular carcinoma. The information provided indicates that the medicine stabilises the disease and may improve survival in some patients in whom previous treatments did not work. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

This medicine attaches to receptors known as A3AR receptors, which are present in abnormally high amounts in liver cancer cells. Once attached to these receptors, the medicine interferes with certain signalling pathways in the cancer cells, resulting in the death of the cells. The medicine is also thought to stimulate the body's immune cells known as 'natural killer cells' to attack the cancer cells, thereby enhancing its anti-cancer effects.

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with hepatocellular carcinoma were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for hepatocellular carcinoma. Orphan designation had been granted in the United States for the condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 3 September 2015 recommending the granting of this designation.

  • the seriousness of the condition;
  • the existence of alternative methods of diagnosis, prevention or treatment;
  • either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

Key facts

Active substance
2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson)
Intended use
Treatment of hepatocellular carcinoma
Orphan designation status
Positive
EU designation number
EU/3/15/1565
Date of designation
Sponsor

Propharma Group The Netherlands B.V.
 

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

DateUpdate
August 2022The sponsorship was transferred from Southwood Research Limited, Netherlands to Propharma Group The Netherlands B.V., Netherlands in August 2022.
June 2021The sponsor's address was updated in June 2021.
March 2020The sponsorship was transferred to Southwood Research Ltd in March 2020. This medicine is now known as namodenoson. 

EMA list of opinions on orphan medicinal product designation

EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Share this page